Sarcoidosis-like reaction during palbociclib treatment for metastatic breast cancer: A case report.
CDK4/6 inhibitor
endoscopic ultrasound-guided fine-needle aspiration
palbociclib
sarcoidosis
sarcoidosis-like
targeted therapy
Journal
The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
19
02
2020
accepted:
20
02
2020
pubmed:
11
4
2020
medline:
22
6
2021
entrez:
11
4
2020
Statut:
ppublish
Résumé
This case report describes a 62-year-old female patient developing a granulomatous sarcoidosis-like reaction in mediastinal lymphatic nodes during a treatment by palbociclib for a metastatic breast carcinoma. After a 3-month treatment associating palbociclib, anastrozole, denosumab, and a single targeted cervical vertebral metastasis radiation therapy, a positron emission tomography showed full regression of breast, vertebral, and axillary node lesion contrasting to new emergent metabolic mediastinal lymph nodes. An endobronchial ultrasound-guided transbronchial needle aspiration revealed a sarcoidosis-like reaction, which dramatically decreased with glucocorticoids.
Substances chimiques
Piperazines
0
Pyridines
0
palbociclib
G9ZF61LE7G
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1239-1241Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646.
Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-915.
Firwana B, Ravilla R, Raval M, Hutchins L, Mahmoud F. Sarcoidosis-like syndrome and lymphadenopathy due to checkpoint inhibitors. J Oncol Pharm Pract. 2017;23(8):620-624.
Grados A, Ebbo M, Bernit E, et al. Sarcoidosis occurring after solid cancer. A nonfortuitous association. Medicine. 2015;94(28):e928.
Lafon M, Blaye C, Kind M, et al. Sarcoidosis- like reaction in metastatic triple negative breast cancer treated by anti-PD-L1. Breast J. 2019;25(5):971-973.
Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN. Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(8):1076-1082.
Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest. 2018;154(3):664-677.
Didier K, Beguinot I, Abou-Taam M, Servettaz A, Bani-Sadr F. Sarcoïdose après chimiothérapie pour adénocarcinome mammaire : difficulté de l’imputabilité médicamenteuse. Therapies. 2017;72(6):705-708.
Arish N, Kuint R, Sapir E, et al. Characteristics of Sarcoidosis in Patients with Previous Malignancy: Causality or Coincidence? Respiration. 2017;93(4):247-252.
Schweitzer MD, Salamo O, Holt G, Donna E, Mirsaeidi M. Sarcoidosis onset after breast cancer; a potential association. Eur J Intern Med. 2017;44:e11-e12.
Cristofanilli M, Turner NC, Slamon D, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425-439.
Ahsan I, Malik F, Jafri SI. Palbociclib related pnemotoxicity: arare side effect. In: C43 drug induced lung disease: case reports. Am Thorac Soc. 2017;A5546-A5546. (American Thoracic Society International Conference Abstracts).